Women’s health – built in rather than bolted on
As the FDA begins lifting hormone therapy warnings, Longevitix argues the next gap is a clinical system designed around the whole woman. For more than two decades, menopausal hormone therapy carried the most prominent safety warning the FDA can print. In February, the agency began taking parts of it
<p>As the FDA begins lifting hormone therapy warnings, Longevitix argues the next gap is a clinical system designed around the whole woman. For more than two decades, menopausal hormone therapy carried the most prominent safety warning the FDA can print. In February, the agency began taking parts of it</p>